ImmuFactIMP321, a biologics developed by Immutep, a French biopharmaceutical company specializing in immune-oncology, and Eddingpharm, a China-based specialty pharmaceutical company,  is being produced to European, U.S., and Chinese GMP standards at WuXi facilities in China.

Using Immutep’s newly developed proprietary cell line, WuXi has begun process development for ImmutepIMP321, which is designed for use in combination with first-line chemotherapy to treat metastatic  breast cancer, metastatic  melanoma, and other cancers.  Manufacturing such first-in-class biologics demonstrates WuXi’s capability as the gateway for developing novel biologics in China.

 

Related links:

WuXi Integrated Biologics Services
WuXi Manufacturing Facility Passes FDA Inspections